osimertinib
astrazeneca
['lung', 'tagrisso', 'astrazeneca']
#astrazeneca reported #tagrisso demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with #egfr mutated #lungcancer #esmo22 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.